Caribou Biosciences, Inc.

About Caribou Biosciences, Inc.

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company leverages next-generation genome-editing technology to develop cell therapies with superior precision, focusing on off-the-shelf allogeneic CAR-T cell therapies for hematologic malignancies and autoimmune diseases. Caribou's pipeline advances readily available treatments designed to be armored for potentially improved activity against diseases. The company emphasizes a collaborative culture where diverse perspectives are valued and team members can work from their Berkeley headquarters or remotely.